JPH06509109A - 選択的トリストミン　ｈ３受容体拮抗薬としてのｓ−（３−（４（５））−イミダゾリル）プロピル）イソチオウレア - Google Patents

選択的トリストミン　ｈ３受容体拮抗薬としてのｓ−（３−（４（５））−イミダゾリル）プロピル）イソチオウレア

Info

Publication number: JPH06509109A
Authority: JP; Japan
Prior art keywords: imidazolyl; propyl; histamine; isothiourea; pharmaceutically acceptable
Prior art date: 1991-07-20
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP5502676A

Other languages

English (en)

Japanese (ja)

Inventor

ハウソン，ウイリアム

Original Assignee

スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-07-20

Filing date

1992-07-16

Publication date

1994-10-13

1992-07-16 Application filed by スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー filed Critical スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー

1994-10-13 Publication of JPH06509109A publication Critical patent/JPH06509109A/ja

Status Pending legal-status Critical Current

Links

125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 title claims description 15
UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 title claims description 15
239000003395 histamine H3 receptor antagonist Substances 0.000 title description 2
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 claims description 32
229960001340 histamine Drugs 0.000 claims description 16
150000003839 salts Chemical class 0.000 claims description 15
239000008194 pharmaceutical composition Substances 0.000 claims description 10
102000005962 receptors Human genes 0.000 claims description 9
108020003175 receptors Proteins 0.000 claims description 9
102000004384 Histamine H3 receptors Human genes 0.000 claims description 7
108090000981 Histamine H3 receptors Proteins 0.000 claims description 7
230000000903 blocking effect Effects 0.000 claims description 5
239000003937 drug carrier Substances 0.000 claims description 4
238000000034 method Methods 0.000 claims description 4
238000007911 parenteral administration Methods 0.000 claims description 3
102000004169 proteins and genes Human genes 0.000 claims description 3
108090000623 proteins and genes Proteins 0.000 claims description 3
241000271569 Rhea Species 0.000 claims 1
239000000126 substance Substances 0.000 claims 1
150000001875 compounds Chemical class 0.000 description 10
239000000203 mixture Substances 0.000 description 10
230000000694 effects Effects 0.000 description 9
239000005557 antagonist Substances 0.000 description 7
239000003814 drug Substances 0.000 description 7
239000000725 suspension Substances 0.000 description 5
239000003826 tablet Substances 0.000 description 5
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
239000000556 agonist Substances 0.000 description 4
239000002775 capsule Substances 0.000 description 4
229940079593 drug Drugs 0.000 description 4
239000012458 free base Substances 0.000 description 4
239000000243 solution Substances 0.000 description 4
-1 (5)-imidazolyl Chemical group 0.000 description 3
XNQIOISZPFVUFG-RXMQYKEDSA-N (R)-alpha-methylhistamine Chemical compound C[C@@H](N)CC1=CN=CN1 XNQIOISZPFVUFG-RXMQYKEDSA-N 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
108010010803 Gelatin Proteins 0.000 description 3
102000003710 Histamine H2 Receptors Human genes 0.000 description 3
108090000050 Histamine H2 Receptors Proteins 0.000 description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
229920000159 gelatin Polymers 0.000 description 3
239000008273 gelatin Substances 0.000 description 3
235000019322 gelatine Nutrition 0.000 description 3
235000011852 gelatine desserts Nutrition 0.000 description 3
239000008187 granular material Substances 0.000 description 3
239000008101 lactose Substances 0.000 description 3
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
102000003834 Histamine H1 Receptors Human genes 0.000 description 2
108090000110 Histamine H1 Receptors Proteins 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
229920000168 Microcrystalline cellulose Polymers 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
239000000443 aerosol Substances 0.000 description 2
229910000147 aluminium phosphate Inorganic materials 0.000 description 2
230000008485 antagonism Effects 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
229940088710 antibiotic agent Drugs 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
235000010980 cellulose Nutrition 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
208000010877 cognitive disease Diseases 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
238000009472 formulation Methods 0.000 description 2
150000002460 imidazoles Chemical class 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
239000007788 liquid Substances 0.000 description 2
YECBIJXISLIIDS-UHFFFAOYSA-N mepyramine Chemical compound C1=CC(OC)=CC=C1CN(CCN(C)C)C1=CC=CC=N1 YECBIJXISLIIDS-UHFFFAOYSA-N 0.000 description 2
229960000582 mepyramine Drugs 0.000 description 2
VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
235000019813 microcrystalline cellulose Nutrition 0.000 description 2
239000008108 microcrystalline cellulose Substances 0.000 description 2
229940016286 microcrystalline cellulose Drugs 0.000 description 2
239000003921 oil Substances 0.000 description 2
235000019198 oils Nutrition 0.000 description 2
239000001267 polyvinylpyrrolidone Substances 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 2
230000004044 response Effects 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
241000700199 Cavia porcellus Species 0.000 description 1
229920000858 Cyclodextrin Polymers 0.000 description 1
239000004338 Dichlorodifluoromethane Substances 0.000 description 1
102000000543 Histamine Receptors Human genes 0.000 description 1
108010002059 Histamine Receptors Proteins 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
208000026139 Memory disease Diseases 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
QKDDJDBFONZGBW-UHFFFAOYSA-N N-Cyclohexy-4-(imidazol-4-yl)-1-piperidinecarbothioamide Chemical compound C1CC(C=2NC=NC=2)CCN1C(=S)NC1CCCCC1 QKDDJDBFONZGBW-UHFFFAOYSA-N 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
241000287462 Phalacrocorax carbo Species 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
239000002253 acid Substances 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000008484 agonism Effects 0.000 description 1
230000003042 antagnostic effect Effects 0.000 description 1
239000008365 aqueous carrier Substances 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
RIMGDBZXWSGBQN-UHFFFAOYSA-N burimamide Chemical compound CNC(=S)NCCCCC1=CN=C[N]1 RIMGDBZXWSGBQN-UHFFFAOYSA-N 0.000 description 1
FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
AQIXAKUUQRKLND-UHFFFAOYSA-N cimetidine Chemical compound N#C/N=C(/NC)NCCSCC=1N=CNC=1C AQIXAKUUQRKLND-UHFFFAOYSA-N 0.000 description 1
229960001380 cimetidine Drugs 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
239000003086 colorant Substances 0.000 description 1
230000008602 contraction Effects 0.000 description 1
239000006071 cream Substances 0.000 description 1
AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
229960003529 diazepam Drugs 0.000 description 1
235000019700 dicalcium phosphate Nutrition 0.000 description 1
229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
210000002249 digestive system Anatomy 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
239000006196 drop Substances 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
238000005538 encapsulation Methods 0.000 description 1
238000011067 equilibration Methods 0.000 description 1
CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
230000000763 evoking effect Effects 0.000 description 1
239000003925 fat Substances 0.000 description 1
235000019197 fats Nutrition 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
235000011087 fumaric acid Nutrition 0.000 description 1
210000004211 gastric acid Anatomy 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
210000003405 ileum Anatomy 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
238000001802 infusion Methods 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
150000002541 isothioureas Chemical class 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
239000012669 liquid formulation Substances 0.000 description 1
239000006210 lotion Substances 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
239000012528 membrane Substances 0.000 description 1
239000002858 neurotransmitter agent Substances 0.000 description 1
230000003957 neurotransmitter release Effects 0.000 description 1
239000002674 ointment Substances 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
239000006072 paste Substances 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000003380 propellant Substances 0.000 description 1
HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
229940044551 receptor antagonist Drugs 0.000 description 1
239000002464 receptor antagonist Substances 0.000 description 1
HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
230000028327 secretion Effects 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
150000004760 silicates Chemical class 0.000 description 1
239000007901 soft capsule Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
229940029284 trichlorofluoromethane Drugs 0.000 description 1
229940116269 uric acid Drugs 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

JP5502676A 1991-07-20 1992-07-16 選択的トリストミン　ｈ３受容体拮抗薬としてのｓ−（３−（４（５））−イミダゾリル）プロピル）イソチオウレア Pending JPH06509109A (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB919115740A GB9115740D0 (en)	1991-07-20	1991-07-20	Medicaments
GB9115740.4		1991-07-20
PCT/GB1992/001299 WO1993001812A1 (en)	1991-07-20	1992-07-16	S-(3-(4(5))-imidazolyl)propyl)isothiourea as selective trhistomine h3 receptor antagonist

Publications (1)

Publication Number	Publication Date
JPH06509109A true JPH06509109A (ja)	1994-10-13

Family

ID=10698725

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP5502676A Pending JPH06509109A (ja)	1991-07-20	1992-07-16	選択的トリストミン　ｈ３受容体拮抗薬としてのｓ−（３−（４（５））−イミダゾリル）プロピル）イソチオウレア

Country Status (5)

Country	Link
EP (1)	EP0595910A1 (de)
JP (1)	JPH06509109A (de)
AU (1)	AU2341192A (de)
GB (1)	GB9115740D0 (de)
WO (1)	WO1993001812A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH09505298A (ja) *	1993-11-15	1997-05-27	シェーリングコーポレイション	Ｈ▲下３▼‐レセプターアンタゴニストとしてのフェニル‐アルキルイミダゾール
US6290986B1 (en)	1996-10-24	2001-09-18	Pharmaceutical Applications Associates, Llc	Method and composition for transdermal administration of pharmacologic agents
US6479074B2 (en)	1996-10-24	2002-11-12	Pharmaceutical Applications Associates Llc	Methods and transdermal compositions for pain relief
US6572880B2 (en)	1996-10-24	2003-06-03	Pharmaceutical Applications Associates Llc	Methods and transdermal compositions for pain relief
US6407132B1 (en)	1997-07-25	2002-06-18	James Black Foundation Limited	Substituted imidazole derivatives and their use as histamine H3 receptor ligands
US6133291A (en) *	1998-10-16	2000-10-17	Schering Corporation	N-(imidazolylalkyl)substituted cyclic amines as histamine-H3 agonists or antagonists
US6211182B1 (en)	1999-03-08	2001-04-03	Schering Corporation	Imidazole compounds substituted with a six or seven membered heterocyclic ring containing two nitrogen atoms
DE19940130A1 (de)	1999-08-24	2001-03-01	Probiodrug Ges Fuer Arzneim	Neue Effektoren der Dipeptidyl Peptidase IV zur topischen Anwendung
AU2001292730A1 (en)	2000-09-20	2002-04-02	Schering Corporation	Substituted imidazoles as dual histamine h1 and h3 agonists or antgonists
AU2001292723A1 (en)	2000-09-20	2002-04-02	Schering Corporation	Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists
WO2002024657A2 (en)	2000-09-20	2002-03-28	Schering Corporation	Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists
CA2422729A1 (en)	2000-09-20	2002-06-06	Schering Corporation	Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists
AU2002253929A1 (en)	2001-02-08	2002-09-24	Schering Corporation	Use of dual h3/m2 antagonists with a bipiperidinic structure in the treatment of cognition deficit disorders
US20030130199A1 (en)	2001-06-27	2003-07-10	Von Hoersten Stephan	Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents
US6844316B2 (en)	2001-09-06	2005-01-18	Probiodrug Ag	Inhibitors of dipeptidyl peptidase I
WO2004098591A2 (en) *	2003-05-05	2004-11-18	Probiodrug Ag	Inhibitors of glutaminyl cyclase and their use in the treatment of neurological diseases
EP1961416B1 (de)	2003-05-05	2013-01-23	Probiodrug AG	Verwendung von Hemmern von Glutaminylcyclase zur Behandlung von Rheumatoider Arthritis, Psoriasis oder Atherosklerose
BRPI0415409A (pt)	2003-10-15	2006-12-05	Probiodrug Ag	uso de efetuadores de ciclases de glutaminila e glutamato
GB0324897D0 (en) *	2003-10-24	2003-11-26	Glaxo Group Ltd	Composition
CA2554809C (en)	2004-02-05	2014-04-29	Probiodrug Ag	Novel n-alkyl thiourea- and thioamide-substituted imidazolyl inhibitors of glutaminyl cyclase
US20160022751A1 (en) *	2014-07-23	2016-01-28	Gangneung-Wonju National University Industry Academy Cooperation Group	Novel composition for treating alzheimer's disease and improving cognitive function of alzheimer's patients

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3759944A (en) *	1970-10-14	1973-09-18	Smith Kline French Lab	Isothioureas and their derivatives
FR2579596B1 (fr) *	1985-03-26	1987-11-20	Inst Nat Sante Rech Med	(imidazolyl-4) piperidines, leur preparation et leur application en therapeutique
GB8916947D0 (en) *	1989-07-25	1989-09-13	Smith Kline French Lab	Medicaments

1991
- 1991-07-20 GB GB919115740A patent/GB9115740D0/en active Pending
1992
- 1992-07-16 WO PCT/GB1992/001299 patent/WO1993001812A1/en not_active Ceased
- 1992-07-16 JP JP5502676A patent/JPH06509109A/ja active Pending
- 1992-07-16 EP EP92915736A patent/EP0595910A1/de not_active Withdrawn
- 1992-07-16 AU AU23411/92A patent/AU2341192A/en not_active Abandoned

Also Published As

Publication number	Publication date
EP0595910A1 (de)	1994-05-11
WO1993001812A1 (en)	1993-02-04
AU2341192A (en)	1993-02-23
GB9115740D0 (en)	1991-09-04

Publication	Publication Date	Title
JPH06509109A (ja)	1994-10-13	選択的トリストミン　ｈ３受容体拮抗薬としてのｓ−（３−（４（５））−イミダゾリル）プロピル）イソチオウレア
DE69121827T2 (de)	1997-02-27	Verwendung von Angiotensin-II-Antagonisten zur Herstellung eines Arzneimittels zur Behandlung von Hyperuricemie
JP2009536176A (ja)	2009-10-08	閉経後の性的欲求障害の治療のためのフリバンセリンの使用
EP0236684A2 (de)	1987-09-16	Galanthamin oder dessen Analoge zur Behandlung der Alzheimerschen Krankheit
JPH06184116A (ja)	1994-07-05	医薬組成物
JP2007518755A (ja)	2007-07-12	モノアミン神経伝達物質再取り込み阻害剤及びｎ−メチル−ｄ−アスパラギン酸（ｎｍｄａ）受容体アンタゴニストを含む医薬組成物
CA2167004C (en)	2006-09-12	Agent for treating mental disorders associated with cerebrovascular disorders
EP0420396B1 (de)	1993-09-08	Imidazol-Derivate als Histamin-H3-Agonisten
RU2282446C2 (ru)	2006-08-27	Лекарственное средство для хронического суставного ревматизма
JP2009530293A (ja)	2009-08-27	チアゾリジンジオン類似体およびグルココルチコイドアゴニストの併用療法
CN117529320A (zh)	2024-02-06	用于治疗病毒感染的rock2抑制剂
JP2002512173A (ja)	2002-04-23	肥満を抑制するための方法
EP1293213A1 (de)	2003-03-19	Prophylactische/therapeutische agentia zur behandlung von postchirurgischen stress
EA007952B1 (ru)	2007-02-27	Применение ирбесартана для изготовления лекарств, которые пригодны для предупреждения или лечения лёгочной артериальной гипертензии
JP2665357B2 (ja)	1997-10-22	心不全治療用医薬組成物
DE69226522T2 (de)	1999-01-07	Herstellung eines medikaments zur behandlung der drogenabhängigkeit
US20090281143A1 (en)	2009-11-12	Dose Reduction of a Cannabinoid CB1 Receptor Antagonist in the Treatment of Overweight or Obesity
JP2002506822A (ja)	2002-03-05	ＧＡＢＡＡα５逆作動薬とニコチン作動薬との組合わせ
TW505639B (en)	2002-10-11	(2-morpholinylmethyl)benzamide derivatives, their preparation and pharmaceutical composition containing the same
JP2001523644A (ja)	2001-11-27	アテローム性動脈硬化症と結びついた動脈血栓合併症を予防するための製薬組成物の製造のためのケトリドの使用
US6372763B1 (en)	2002-04-16	Treatment and prevention of cardiac disorders using selective serotonin re-uptake inhibitors (SSRI)
JP2798588B2 (ja)	1998-09-17	抗菌剤
IT8448082A1 (it)	1985-10-20	Composto farmaceutico a base d diidroergotossina per il trattamento dell'ipertensione
SK227092A3 (en)	1996-02-07	Pharmaceutical agent against the high blood pressure
JP3272369B2 (ja)	2002-04-08	イミダゾール誘導体を含有する抗ｈｉｖ組成物

JPH06509109A - 選択的トリストミン ｈ３受容体拮抗薬としてのｓ−（３−（４（５））−イミダゾリル）プロピル）イソチオウレア - Google Patents